Unique ID issued by UMIN | UMIN000019096 |
---|---|
Receipt number | R000022011 |
Scientific Title | Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents |
Date of disclosure of the study information | 2015/09/24 |
Last modified on | 2019/05/10 23:54:42 |
Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents
Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents
Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents
Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents
Japan |
Type 2 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
The aim of this study is to compare efficacy and safety between dulaglutide and exenatide extended-release in type 2 diabetes mellitus patients who are controlled insufficiently with oral antidiabetic agents.
Safety,Efficacy
Pragmatic
Not applicable
Change of HbA1c,body weight at the 52th and the 104th week.
As for patients with renal disturbance, change of serum creatinine, urine albumin(mg/gCr), urine protein (g/gCr) at the 52th and the 104th week.
As for patients over 70 years old, change of MMSE at the 52th and the 104th week.
Change of data shown below at the 52th and the 104th week.
AST, ALT, gamma-GTP, LDL-C, HDL-C,TG, non-HOL-C, serum creatinine, serum UA, eGFR, 1,5-AG, self-monitoring blood glucose, Urine albumin(mg/gCr),Urine protein (g/gCr)
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
2
Treatment
Medicine |
From the start to the end of the study patients are treated with exenatide extended-release every week.
From the start to the end of the study patients are treated with dulaglutide every week.
20 | years-old | <= |
90 | years-old | >= |
Male and Female
HbA1c is higher than or equal to 6.5% or BMI is higher than or equal to 25.
Patients are not planned to be treated with prohibited combined drugs.
Type 1 diabetes mellitus patients.
Patients with a history of severe ketosis or diabetic coma in previous 6 months.
Patients with severe infection, before/after surgery or with severe traumatic injury.
Patients to have a plan to be pregnant.
Patients with severe gastroenteric disturbance as exemplified by severe gastro-paresis.
Patients with a history of pancreatitis.
75
1st name | |
Middle name | |
Last name | Tatsuya Haga |
Haga Diabetes Clinic
Internal Medicine
3514-1 Teigaishinden Nishiho-cho Aisai Aichi Japan
0567-28-7700
tatsuya-umin@hagadm.com
1st name | |
Middle name | |
Last name | Tatsuya Haga |
Haga Diabetes Clinic
Internal Medicine
3514-1 Teigaishinden Nishiho-cho Aisai Aichi Japan
0567-28-7700
tatsuya-umin@hagadm.com
Haga Diabetes Clinic
self-procurement
Self funding
NO
羽賀糖尿病内科(愛知県)
2015 | Year | 09 | Month | 24 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 09 | Month | 11 | Day |
2015 | Year | 09 | Month | 15 | Day |
2015 | Year | 09 | Month | 24 | Day |
2020 | Year | 12 | Month | 31 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 06 | Month | 30 | Day |
2021 | Year | 12 | Month | 31 | Day |
2015 | Year | 09 | Month | 23 | Day |
2019 | Year | 05 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022011